A Comprehensive Approach to Managing Methamphetamine-Associated Cardiomyopathy.
Journal
American journal of cardiovascular drugs : drugs, devices, and other interventions
ISSN: 1179-187X
Titre abrégé: Am J Cardiovasc Drugs
Pays: New Zealand
ID NLM: 100967755
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
accepted:
13
01
2022
pubmed:
15
2
2022
medline:
14
7
2022
entrez:
14
2
2022
Statut:
ppublish
Résumé
Methamphetamines are illicit drugs of the amphetamine-type stimulant class that have been increasing in popularity, availability, and purity in recent decades. As a result, rates of methamphetamine-associated cardiomyopathy (MAC) are rising globally. MAC is associated with high rates of sudden cardiac arrest, late presentation, and poor outcomes. This review discusses the medical management of MAC, including anticipated challenges specific to methamphetamine users. Not only are patients with MAC more likely to present at a younger age and with multisystem disease than patients with cardiomyopathy of other etiologies, but there may also be significant behavioral, psychosocial, financial, and system-based challenges to providing the best medical care. An individualized treatment plan that emphasizes methamphetamine abstinence as the foundation of therapy, as well as introducing optimal heart failure therapy and providing multidisciplinary support is likely to result in optimal outcomes. Given the potential reversibility of MAC, institution of guideline-directed heart failure therapy and patient support for adherence to therapy and abstinence from methamphetamines should be energetically pursued.
Identifiants
pubmed: 35157254
doi: 10.1007/s40256-022-00523-y
pii: 10.1007/s40256-022-00523-y
doi:
Substances chimiques
Central Nervous System Stimulants
0
Methamphetamine
44RAL3456C
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
385-393Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Paratz ED, Cunningham NJ, MacIsaac AI. The Cardiac complications of methamphetamines. Heart Lung Circ. 2016;25(4):325–32. https://doi.org/10.1016/j.hlc.2015.10.019 .
doi: 10.1016/j.hlc.2015.10.019
pubmed: 26706652
Thomas IC, Nishimura M, Ma J, Dickson SD, Alshawabkeh L, Adler E, Maisel A, Criqui MH, Greenberg B. Clinical characteristics and outcomes of patients with heart failure and methamphetamine abuse. J Card Fail. 2020;26(3):202–9. https://doi.org/10.1016/j.cardfail.2019.10.002 .
doi: 10.1016/j.cardfail.2019.10.002
pubmed: 31618697
McKetin R. llicit drug use in Australia: epidemiology, use patterns and associated harm, (2nd edition). In: Ross J (ed) National Drug & Alcohol Research Centre; 2007.
World Drug Report 2021 (United Nations publication, Sales No. E.21.XI.8). 2021. https://www.unodc.org/res/wdr2021/field/WDR21_Booklet_1.pdf .
Australian Criminal Intelligence Commission, Illicit Drug Data Report. 2018–19 (Canberra 2020). 2020. https://www.acic.gov.au/sites/default/files/2020-09/illicit_drug_data_report_2018-19_internals_v10_full.pdf .
United States, Department of Justice, Drug Enforcement Administration, 2020 National Drug Threat Assessment. 2021. https://www.dea.gov/sites/default/files/2021-02/DIR-008-21%202020%20National%20Drug%20Threat%20Assessment_WEB.pdf .
Dickson SD, Thomas IC, Bhatia HS, Nishimura M, Mahmud E, Tu XM, Lin T, Adler E, Greenberg B, Alshawabkeh L. Methamphetamine-associated heart failure hospitalizations across the United States: geographic and social disparities. J Am Heart Assoc. 2021;10(16): e018370. https://doi.org/10.1161/JAHA.120.018370 .
doi: 10.1161/JAHA.120.018370
pubmed: 34365802
pmcid: 8475042
Alcohol, tobacco & other drugs in Australia. In: Australian Institute of Health and Welfare. 2021. https://www.aihw.gov.au/reports/alcohol/alcohol-tobacco-other-drugs-australia .
Richards JR, Albertson TE, Derlet RW, Lange RA, Olson KR, Horowitz BZ. Treatment of toxicity from amphetamines, related derivatives, and analogues: a systematic clinical review. Drug Alcohol Depend. 2015;1(150):1–13. https://doi.org/10.1016/j.drugalcdep.2015.01.040 .
doi: 10.1016/j.drugalcdep.2015.01.040
Reddy PKV, Ng TMH, Oh EE, Moady G, Elkayam U. Clinical characteristics and management of methamphetamine-associated cardiomyopathy: state-of-the-art review. J Am Heart Assoc. 2020;9(11): e016704. https://doi.org/10.1161/JAHA.120.016704 .
doi: 10.1161/JAHA.120.016704
pubmed: 32468897
pmcid: 7428977
Darke S, Duflou J, Kaye G. Prevalence and nature of cardiovascular disease in methamphetamine-related death: a national study. Drug Alcohol Depend. 2017;179:174–9. https://doi.org/10.1016/j.drugalcdep.2017.07.001 .
doi: 10.1016/j.drugalcdep.2017.07.001
pubmed: 28787694
Hart CL, Gunderson EW, Perez A, et al. Acute physiological and behavioral effects of intranasal methamphetamine in humans. Neuropsychopharmacology. 2008;33:1847–55.
doi: 10.1038/sj.npp.1301578
Orcholski ME, Khurshudyan A, Shamskhou EA, Yuan K, Chen IY, Kodani SD, Morisseau C, Hammock BD, Hong EM, Alexandrova L, et al. Reduced carboxylesterase 1 is associated with endothelial injury in methamphetamine-induced pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 2017;313:L252–66.
doi: 10.1152/ajplung.00453.2016
Wijetunga M, Seto T, Lindsay J, Schatz I. Crystal methamphetamine-associated cardiomyopathy: tip of the iceberg? J Toxicol Clin Toxicol. 2003;41:981–6.
doi: 10.1081/CLT-120026521
He SY, Matoba R, Fujitani N, Sodesaki K, Onishi S. Cardiac muscle lesions associated with chronic administration of methamphetamine in rats. Am J Forensic Med Pathol. 1996;17:155–62.
doi: 10.1097/00000433-199606000-00014
Pujol-López M, Ortega-Paz L, Flores-Umanzor EJ, Perea RJ, Bosch X. Cardiac magnetic resonance as an alternative to endomyocardial biopsy to predict recoverability of left ventricular function in methamphetamine—associated cardiomyopathy. JACC Heart Fail. 2017;5:853–4.
doi: 10.1016/j.jchf.2017.08.009
Karch SB. The unique histology of methamphetamine cardiomyopathy: a case report. Forensic Sci Int. 2011;212:e1–4.
doi: 10.1016/j.forsciint.2011.04.028
Jafari GM. Exposure to amphetamines leads to development of amphetamine type stimulants associated cardiomyopathy (ATSAC). Cardiovasc Toxicol. 2017;17:13–24.
doi: 10.1007/s12012-016-9385-8
Qu YH, Leung KP, Qiao DF, Li DR, Liu C, Yue X, Wang HJ. Remodeling of ion channel expression may contribute to electrophysiological consequences caused by methamphetamine in vitro and in vivo. Biochem Biophys Res Commun. 2014;443:441–6.
doi: 10.1016/j.bbrc.2013.11.114
Parekh JD, Jani V, Patel U, Aggarwal G, Thandra A, Arora R. Methamphetamine use is associated with increased risk of stroke and sudden cardiac death: analysis of the nationwide inpatient sample database. JACC Cardiovasc Interv. 2018;11:S29.
doi: 10.1016/j.jcin.2018.01.093
Darke S, Kaye S, Duflou J. Rates, characteristics and circumstances of methamphetamine-related death in Australia: a national 7-year study. Addiction. 2017;112:2191–201.
doi: 10.1111/add.13897
Schürer S, Klingel K, Sandri M, Majunke N, Besler C, Kandolf R, Lurz P, Luck M, Hertel P, Schuler G, Linke A, Mangner N. Clinical characteristics, histopathological features, and clinical outcome of methamphetamine-associated cardiomyopathy. JACC Heart Fail. 2017;5(6):435–45. https://doi.org/10.1016/j.jchf.2017.02.017 (Erratum in: JACC Heart Fail. 2017 Aug;5(8):620).
doi: 10.1016/j.jchf.2017.02.017
pubmed: 28571597
Dalal S, Arustamyan M, Marmolejos G, Ramakrishna K. Delayed cardiomyopathy and cardiogenic shock due to intravenous methamphetamine use requiring hemodynamic support with veno-arterial extracorporeal membrane oxygenation. JACEP Open. 2020;1:117–9.
doi: 10.1002/emp2.12027
Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, Blankstein R, Boyd J, Bullock-Palmer RP, Conejo T, Diercks DB, Gentile F, Greenwood JP, Hess EP, Hollenberg SM, Jaber WA, Jneid H, Joglar JA, Morrow DA, O’Connor RE, Ross MA, Shaw LJ. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology/American Heart Association Joint committee on clinical practice guidelines. Circulation. 2021;2021:CIR0000000000001029. https://doi.org/10.1161/CIR.0000000000001029 .
doi: 10.1161/CIR.0000000000001029
Paratz ED, Zhao J, Sherwen AK, Scarlato RM, MacIsaac AI. Is an abnormal ECG just the tip of the ICE-berg? Examining the utility of electrocardiography in detecting methamphetamine-induced cardiac pathology. Heart Lung Circ. 2017;26(7):684–9. https://doi.org/10.1016/j.hlc.2016.11.005 .
doi: 10.1016/j.hlc.2016.11.005
pubmed: 28110851
Ito H, Yeo KK, Wijetunga M, Seto TB, Tay K, Schatz IJ. A comparison of echocardiographic findings in young adults with cardiomyopathy: with and without a history of methamphetamine abuse. Clin Cardiol. 2009;32:E18–22.
doi: 10.1002/clc.20367
Voskoboinik A, Ihle JF, Bloom JE, Kaye DM. Methamphetamine-associated cardiomyopathy: patterns and predictors of recovery. Intern Med J. 2016;46:723–7. https://doi.org/10.1111/imj.13050 .
doi: 10.1111/imj.13050
pubmed: 26929061
Reddy PK, Chau E, Patel SV, Yang K, Ng TM, Elkayam U. Characteristics of methamphetamine-associated cardiomyopathy and the impact of methamphetamine use on cardiac dysfunction. Am J Cardiol. 2021;1(154):86–91. https://doi.org/10.1016/j.amjcard.2021.06.001 .
doi: 10.1016/j.amjcard.2021.06.001
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726. https://doi.org/10.1093/eurheartj/ehab368 .
Bozkurt B, Hershberger RE, Butler J, Grady KL, Heidenreich PA, Isler ML, Kirklin JK, Weintraub WS. 2021 ACC/AHA key data elements and definitions for heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (writing committee to develop clinical data standards for heart failure). Circ Cardiovasc Qual Outcomes. 2021;14(4): e000102. https://doi.org/10.1161/HCQ.0000000000000102 .
doi: 10.1161/HCQ.0000000000000102
pubmed: 33755495
pmcid: 8059763
Kevil CG, Goeders NE, Woolard MD, Bhuiyan MS, Dominic P, Kolluru GK, Arnold CL, Traylor JG, Orr AW. Methamphetamine use and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2019;39(9):1739–46. https://doi.org/10.1161/ATVBAHA.119.312461 .
doi: 10.1161/ATVBAHA.119.312461
pubmed: 31433698
pmcid: 6709697
Lopez JE, Yeo K, Caputo G, Buonocore M, Schaefer S. Recovery of methamphetamine associated cardiomyopathy predicted by late gadolinium enhanced cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2009;11(1):46. https://doi.org/10.1186/1532-429X-11-46 .
doi: 10.1186/1532-429X-11-46
pubmed: 19906310
pmcid: 2780987
Zhao SX, Seng S, Deluna A, Yu EC, Crawford MH. Comparison of clinical characteristics and outcomes of patients with reversible versus persistent methamphetamine-associated cardiomyopathy. Am J Cardiol. 2020;125(1):127–34. https://doi.org/10.1016/j.amjcard.2019.09.030 .
doi: 10.1016/j.amjcard.2019.09.030
pubmed: 31699360
Grigg J, Manning V, Arunogiri S, Volpe I, Frei M, Phan V, Rubenis A, Dias S, Petrie M, Sharkey M, Lubman DI. Methamphetamine treatment guidelines: practice guidelines for health professionals (Second Edition). Richmond, Victoria: Turning Point. 2018. http://s3-ap-southeast-2.amazonaws.com/turning-point-website-prod/drupal/2019-05/Turning-Point-Methamphetamine-Treatment-Guidelines.pdf .
Karila L, Weinstein A, Aubin HJ, Benyamina A, Reynaud M, Batki SL. Pharmacological approaches to methamphetamine dependence: a focused review. Br J Clin Pharmacol. 2010;69(6):578–92. https://doi.org/10.1111/j.1365-2125.2010.03639 .
doi: 10.1111/j.1365-2125.2010.03639
pubmed: 20565449
pmcid: 2883750
Harney A, Lee N, Jenner L. Evaluation of torque-a catalyst non-residential program [Internet]. 2015. http://360edge.com.au/assets/uploads/2017/01/Torque_Final_Report_Dec15.pdf . Accessed Nov 2021.
Wang TKM, Kueh SA, Sutton T, Gabriel R, Lund M, Looi JL. Poor outcomes in methamphetamine-associated cardiomyopathy—a growing health issue in New Zealand. N Z Med J. 2019;132(1502):55–66.
pubmed: 31563927
NHFA CSANZ Heart Failure Guidelines Working Group, Atherton JJ, Sindone A, De Pasquale CG, Driscoll A, MacDonald PS, Hopper I, Kistler PM, Briffa T, Wong J, Abhayaratna W, Thomas L, Audehm R, Newton P, O'Loughlin J, Branagan M, Connell C. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: guidelines for the prevention, detection, and management of heart failure in Australia 2018. Heart Lung Circ. 2018;27(10):1123–1208. https://doi.org/10.1016/j.hlc.2018.06.1042 .
Lange RA, Cigarroa RG, Flores ED, McBride W, Kim AS, Wells PJ, et al. Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade. Ann Intern Med. 1990;112:897–903.
doi: 10.7326/0003-4819-112-12-897
Ramachandran R, Rewari V. Current perioperative management of pheochromocytomas. Indian J Urol. 2017;33(1):19–25. https://doi.org/10.4103/0970-1591.194781 .
doi: 10.4103/0970-1591.194781
pubmed: 28197025
pmcid: 5264186
Nguyen P, Kamran H, Nasir S, Chan W, Shah T, Deswal A, Bozkurt B. Comparison of frequency of cardiovascular events and mortality in patients with heart failure using versus not using cocaine. Am J Cardiol. 2017;119(12):2030–4. https://doi.org/10.1016/j.amjcard.2017.03.034 .
doi: 10.1016/j.amjcard.2017.03.034
pubmed: 28456314
Zhao SX, Kwong C, Swaminathan A, Gohil A, Crawford MH. Clinical characteristics and outcome of methamphetamine-associated pulmonary arterial hypertension and dilated cardiomyopathy. JACC Heart Fail. 2018;6:209–18.
doi: 10.1016/j.jchf.2017.10.006
Sliman S, Waalen J, Shaw D. Methamphetamine-associated congestive heart failure: increasing prevalence and relationship of clinical outcomes to continued use or abstinence. Cardiovasc Toxicol. 2016;16(4):381–9. https://doi.org/10.1007/s12012-015-9350-y .
doi: 10.1007/s12012-015-9350-y
pubmed: 26661075
Bhatia HS, Nishimura M, Martinez A, Vanam S, Kahn AM, DeMaria A, Thomas IC. Systolic dysfunction in patients with methamphetamine use and heart failure with preserved ejection fraction. Int J Cardiol. 2021. https://doi.org/10.1016/j.ijcard.2021.12.024 .
doi: 10.1016/j.ijcard.2021.12.024
pubmed: 34921901